SPARC and neoplasm: In vivo, albumin nanoparticles are recognized by albumin receptor gp60; nab-paclitaxel then penetrates vascular endothelial cells by vesicular transport, enters tumor tissue, and binds to secreted acidic and cysteine-rich protein (SPARC), eventually being retained in tumor cells (29–31).